Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Disruption of pancreatic clock genes impairs pancreatic beta-cell function, leading to the onset of diabetes. Despite the importance of pancreatic alpha-cells in the regulation of glucose homeostasis and in diabetes pathophysiology, nothing is known about the role of clock genes in these cells. Here, we identify the clock gene
Rev-erb alpha
as a new intracellular regulator of
glucagon
secretion.
Rev-erb alpha
down-regulation by siRNA (60-70% inhibition) in alphaTC1-9 cells inhibited low-glucose induced
glucagon
secretion (p<0.05) and led to a decrease in key genes of the exocytotic machinery. The
Rev-erb alpha
agonist GSK4112 increased
glucagon
secretion (1.6 fold) and intracellular calcium signals in alphaTC1-9 cells and mouse primary alpha-cells, whereas the
Rev-erb alpha
antagonist SR8278 produced the opposite effect. At 0.5 mM glucose, alphaTC1-9 cells exhibited intrinsic circadian
Rev-erb alpha
expression oscillations that were inhibited by 11 mM glucose. In mouse primary alpha-cells, glucose induced similar effects (p<0.001). High glucose inhibited key genes controlled by AMPK such as Nampt, Sirt1 and PGC-1 alpha in alphaTC1-9 cells (p<0.05). AMPK activation by metformin completely reversed the inhibitory effect of glucose on Nampt-Sirt1-PGC-1 alpha and
Rev-erb alpha
. Nampt inhibition decreased Sirt1, PGC-1 alpha and
Rev-erb alpha
mRNA expression (p<0.01) and
glucagon
release (p<0.05). These findings identify
Rev-erb alpha
as a new intracellular regulator of
glucagon
secretion via AMPK/Nampt/Sirt1 pathway.
...
PMID:Involvement of the clock gene Rev-erb alpha in the regulation of glucagon secretion in pancreatic alpha-cells. 2393 24